PL2240572T3 - Wykorzystanie rna dla przeprogramowania komórek somatycznych - Google Patents

Wykorzystanie rna dla przeprogramowania komórek somatycznych

Info

Publication number
PL2240572T3
PL2240572T3 PL08861423T PL08861423T PL2240572T3 PL 2240572 T3 PL2240572 T3 PL 2240572T3 PL 08861423 T PL08861423 T PL 08861423T PL 08861423 T PL08861423 T PL 08861423T PL 2240572 T3 PL2240572 T3 PL 2240572T3
Authority
PL
Poland
Prior art keywords
rna
programming
somatic cell
somatic
cell
Prior art date
Application number
PL08861423T
Other languages
English (en)
Inventor
Ugur Sahin
Marco Poleganov
Tim Beissert
Original Assignee
Biontech Ag
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Ag
Publication of PL2240572T3 publication Critical patent/PL2240572T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
PL08861423T 2007-12-14 2008-12-12 Wykorzystanie rna dla przeprogramowania komórek somatycznych PL2240572T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07024312A EP2072618A1 (en) 2007-12-14 2007-12-14 Use of RNA for reprogramming somatic cells
EP08861423.5A EP2240572B1 (en) 2007-12-14 2008-12-12 Use of rna for reprogramming somatic cells
PCT/EP2008/010593 WO2009077134A2 (en) 2007-12-14 2008-12-12 Use of rna for reprogramming somatic cells

Publications (1)

Publication Number Publication Date
PL2240572T3 true PL2240572T3 (pl) 2015-08-31

Family

ID=39472686

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08861423T PL2240572T3 (pl) 2007-12-14 2008-12-12 Wykorzystanie rna dla przeprogramowania komórek somatycznych

Country Status (12)

Country Link
US (5) US20110065103A1 (pl)
EP (3) EP2072618A1 (pl)
JP (3) JP6231253B2 (pl)
CY (1) CY1116226T1 (pl)
DK (1) DK2240572T3 (pl)
ES (1) ES2532125T3 (pl)
HR (1) HRP20150194T1 (pl)
HU (1) HUE025698T2 (pl)
PL (1) PL2240572T3 (pl)
PT (1) PT2240572E (pl)
SI (1) SI2240572T1 (pl)
WO (1) WO2009077134A2 (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
AU2008297024B2 (en) * 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
ES2587395T3 (es) * 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
WO2010019569A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International. Inc. Methods for the production of ips cells
EP3450545B1 (en) * 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
EP2881461A1 (en) * 2008-11-21 2015-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
RU2399667C1 (ru) * 2009-04-10 2010-09-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения плюрипотентных клеток
JP5777113B2 (ja) * 2009-05-29 2015-09-09 学校法人慶應義塾 人工多能性幹細胞のクローンの選択方法
CN105925535A (zh) 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
JP2011004674A (ja) * 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
WO2011058558A2 (en) 2009-11-12 2011-05-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US12655395B2 (en) 2009-12-07 2026-06-16 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
US20130189741A1 (en) * 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
AU2015215938B2 (en) * 2009-12-07 2018-01-18 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
ES2769129T3 (es) * 2009-12-07 2020-06-24 Univ Pennsylvania Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
WO2011130624A2 (en) * 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
AU2011268056B2 (en) 2010-06-18 2014-04-24 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012072096A1 (en) * 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
US20140024119A1 (en) * 2011-01-14 2014-01-23 Korea Research Institute Of Bioscience And Biotechnology Cell reprogramming composition comprising rex1 and an induced pluripotent stem cell production method using the same
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013078199A2 (en) * 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP3260140B1 (en) 2011-12-05 2021-02-03 Factor Bioscience Inc. Methods and products for transfecting cells
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
DK3421601T3 (da) 2011-12-30 2020-02-24 Cellscript Llc Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013266496B2 (en) 2012-05-21 2018-08-09 The Regents Of The University Of California Generation of human iPS cells by a synthetic self- replicative RNA
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
GB201601503D0 (en) 2016-01-27 2016-03-09 Isis Innovation Dendritic cells
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017196175A1 (en) 2016-05-12 2017-11-16 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium.
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
KR102167826B1 (ko) * 2018-05-09 2020-10-20 주식회사 강스템바이오텍 Sox2, c-Myc를 이용하여 비신경 세포로부터 직접 리프로그래밍된 유도신경줄기세포를 제조하는 방법
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3114892A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
WO2022232802A1 (en) * 2021-04-29 2022-11-03 Maxcyte, Inc. Sequential electroporation methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002300876A (ja) * 2001-04-03 2002-10-15 Nagoya Industrial Science Research Inst 組織を形成する細胞内で外来遺伝子を発現させる方法
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
CA2513226A1 (en) * 2003-01-13 2004-07-29 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US7846731B2 (en) * 2003-10-08 2010-12-07 Kyoto University Method of introducing nucelic acid
JP4575923B2 (ja) * 2003-12-15 2010-11-04 カレッジ オブ メディスン ポーチョン シーエイチエー ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーション ヒトＥＳ細胞より分離された新規ｍｉＲＮＡ
WO2005080598A1 (ja) * 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
JP4731867B2 (ja) * 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
JP2007312782A (ja) * 2004-11-18 2007-12-06 Hiroshima Univ 遺伝子増幅により形成された反復配列から、発現抑制されているタンパク質を発現させる方法、キット、および形質転換体
EP1876233A1 (en) * 2005-01-24 2008-01-09 Japan Health Sciences Foundation Cells capable of differentiating into cardiac muscle cells
JP2008193897A (ja) * 2005-04-19 2008-08-28 Nara Institute Of Science & Technology 多能性幹細胞増殖促進剤
JP4685531B2 (ja) * 2005-07-11 2011-05-18 ローム株式会社 降圧型スイッチングレギュレータおよびその制御回路ならびにそれを用いた電子機器
JP2007082436A (ja) * 2005-09-20 2007-04-05 Bioinformatics Institute For Global Good Inc 機能性ＲＮＡが制御するターゲットｍＲＮＡの予測・同定方法及びその利用方法
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
EP2206724A1 (en) * 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP1986667A1 (en) * 2006-02-22 2008-11-05 Argos Therapeutics, Inc. Dendritic cells transiently transfected with a membrane homing polypeptide and their use
WO2008097926A2 (en) 2007-02-02 2008-08-14 Yale University Transient transfection with rna
KR101532442B1 (ko) * 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법

Also Published As

Publication number Publication date
US12378531B2 (en) 2025-08-05
WO2009077134A2 (en) 2009-06-25
US11008550B2 (en) 2021-05-18
JP2011505814A (ja) 2011-03-03
EP2240572A2 (en) 2010-10-20
HUE025698T2 (en) 2016-04-28
JP2015198664A (ja) 2015-11-12
JP6231253B2 (ja) 2017-11-15
ES2532125T3 (es) 2015-03-24
JP2018134102A (ja) 2018-08-30
US20170218342A1 (en) 2017-08-03
CY1116226T1 (el) 2017-03-15
PT2240572E (pt) 2015-04-07
US20190194623A1 (en) 2019-06-27
EP2240572B1 (en) 2015-02-11
US20210324341A1 (en) 2021-10-21
JP6648187B2 (ja) 2020-02-14
DK2240572T3 (en) 2015-03-09
SI2240572T1 (sl) 2015-07-31
EP2896690A2 (en) 2015-07-22
EP2072618A1 (en) 2009-06-24
EP2896690A3 (en) 2015-08-19
US20110065103A1 (en) 2011-03-17
WO2009077134A3 (en) 2009-08-27
HRP20150194T1 (hr) 2015-06-05
US20160122721A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
BRPI0820020A2 (pt) Material anticorrosão
SI2240572T1 (sl) Uporaba RNA za reprogramiranje somatskih celic
EP2145000A4 (en) NEW PROGRAMMING OF BODY CELLS
DK3399025T3 (da) Omprogrammering af somatiske celler
DK3375867T3 (da) Feeder-frit kultursystem
DK2155852T3 (da) Forbedret fleksibel bioreaktor
EP2134446A4 (en) BIOGAS PROCESSING
DK2164893T3 (da) Polyethylenskum
EP2233838A4 (en) COOKER
BRPI0913945A2 (pt) agentes anti-inflamatórios
FI20075368L (fi) Oksasakset
ATE510923T1 (de) Nukleinsäure
ATE515289T1 (de) Arylether-pyridazinonderivate
BRPI0815203A2 (pt) gel contendo pirfenidona
BRPI0814572A2 (pt) Célula de lítio
EP2130901A4 (en) Culture apparatus
EP2192402A4 (en) Enzyme electrode
CR9342S (es) Regadera
BRPI0813726A2 (pt) Célula de lítio
DE102007047112A8 (de) Strahlregler
BRPI0817439A2 (pt) gaseificador
SE0701400L (sv) Odlingssystem
FI20070190A0 (fi) Bioreaktori
FR2918073B1 (fr) Cellules fixatrices de cellules tumorales.